Lionsgate Studios (NYSE: LION) insider transactions
In the twelve months to 10 November 2026, executives and directors of Lionsgate Studios reported 8 open-market sales of 42,842,245 shares ($2.0m) and 7 open-market purchases of 42,600,497 shares ($0), by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 15 September 2026 | Fine Emily | Director | Grant or award | +4,468 | $11.19 | 141,256 | Form 4 |
| 15 September 2026 | Fine Emily | Director | Grant or award | +13,405 | $11.19 | 13,405 | Form 4 |
| 15 September 2026 | Rachesky Mark H MD | Director | Grant or award | +6,792 | $11.19 | 269,004 | Form 4 |
| 15 September 2026 | Rachesky Mark H MD | Director | Grant or award | +13,405 | $11.19 | 13,405 | Form 4 |
| 15 September 2026 | Harkey John D JR | Director | Grant or award | +13,405 | — | 221,593 | Form 4 |
| 15 September 2026 | Harkey John D JR | Director | Grant or award | +5,809 | $11.19 | 227,402 | Form 4 |
| 15 September 2026 | Sloan Harry | Director | Grant or award | +13,405 | — | 429,318 | Form 4 |
| 15 September 2026 | Sloan Harry | Director | Grant or award | +5,362 | $11.19 | 434,680 | Form 4 |
| 15 September 2026 | Rosenblatt M Richard | Director | Grant or award | +13,405 | — | 74,202 | Form 4 |
| 15 September 2026 | Rosenblatt M Richard | Director | Grant or award | +4,468 | $11.19 | 78,670 | Form 4 |
| 15 September 2026 | Crawford Gordon | Director | Grant or award | +13,405 | — | 2,259,635 | Form 4 |
| 15 September 2026 | Crawford Gordon | Director | Grant or award | +4,468 | $11.19 | 2,264,103 | Form 4 |
| 15 September 2026 | McCaw Susan | Director | Grant or award | +13,405 | — | 114,431 | Form 4 |
| 15 September 2026 | Ostolaza Yvette | Director | Grant or award | +13,405 | — | 161,225 | Form 4 |
| 15 September 2026 | Ostolaza Yvette | Director | Grant or award | +5,362 | $11.19 | 166,587 | Form 4 |
| 8 July 2026 | Rachesky Mark H MD | Director | Open-market sale | −1,469,450 | — | 0 | Form 4 |
| 8 July 2026 | Rachesky Mark H MD | Director | Open-market sale | −3,701,988 | — | 0 | Form 4 |
| 8 July 2026 | Rachesky Mark H MD | Director | Open-market sale | −25,173,882 | — | 0 | Form 4 |
| 8 July 2026 | Rachesky Mark H MD | Director | Open-market purchase | +797,526 | — | 797,526 | Form 4 |
| 8 July 2026 | Rachesky Mark H MD | Director | Open-market purchase | +1,916,271 | — | 1,916,271 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Lionsgate Studios page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.